Um.. immune therapies, targeted genetic therapies, TIL therapies... all kind of a big deal.
Sorry, you don't know what you're talking about.
And rates say nothing about efficacy / quality of treatment. (And even when new treatments are not more effective, often the side effects are much milder (to non-existent): getting an extra three years sick and in pain, vs getting them as your normal self is a huge difference)
Edit: what I mean by that is that rates of incidence say nothing about how effective the treatments are. It can both be true that rates are going up (say, due to air pollution) and that treatments are more effective.
---
Reply to comment below: again, you are wrong. Jesus, stop. One example: Ipilimumab and PD-1 inhibitors have a ~20% effectiveness rate against melanoma, a cancer that was considered a sure death sentence just 15 years ago. Some patients have not had any recurrence in a decade, they seem cured, which was unheard of before.
And targeted drugs like dabrafenib buy most patients an extra 6-18 months, almost side effect free. With more of these coming out, it seems like soon it'll be possible to cycle patients even longer (some combos already are known to extend their effect).
This doesn't qualify as "major"? The ability to reprogram our immune system to kill cancer cells, or to reprogram pathways in faulty cells?